TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03681561: Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Sponsor: Veronika Bachanova · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT03681561 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03681561 Rescue Dossier →